Shin E, Lim DH, Han J, et al. - Utilizing medical chart review conducted at Samsung Medical Center, Seoul, Republic of Korea, researchers described corneal epithelial changes after using epidermal (EGFR) or fibroblast growth factor receptor (FGFR) inhibitors as chemotherapy and clarified prognosis and incidence. Of 6,871 individuals and 17 EGFR or FGFR inhibitors, 1,161 referred for ophthalmologic examination. A total of 1,145 patients had disease-related or unrelated ocular complications. Findings suggested that inhibitors of EGFR and FGFR are chemotherapy agents that may cause changes in the corneal epithelium. Recently introduced EGFR and FGFR agents showed a high incidence of ocular complication with severe vision distortion, compared with the low probability of ocular complication with old EGFR medicines. Doctors will warn patients undergoing chemotherapy with these agents that could cause decreased visual acuity due to corneal epithelial changes and also inform them that the condition could be improved after the completion of the treatment without using steroid eye drops.